Clouds and artificial intelligence are the most recent innovation allies in the production of medications. “The healthcare industry is one of the threads that more attracts investments in technology and new products. Now, with the use of clouds and artificial intelligence new ways to accelerate the development of medicinal products should emerge “, says Arie Halpern, economist, and entrepreneur with a focus on innovation and disruptive technologies.
The Canadian company Deep Genomics has associated AI and deep learning. Founded by Brendan Frey, the company became known for using these technologies in research for the use of genetic potential in curing illnesses. In May this year, the company announced that it will channel efforts to the development of medications. In the first stage, the company will focus on medicines for kinds of genetic diseases known as Mendelian disorders. “It is understandable that part of this change in the company’s aim comes from the fact that it has accumulated a large amount of data about genetic diseases. It Is now able to use algorithms to analyze the data and get good results “, says Arie Halpern. According to Frey, the best way to handle large amounts of data is through artificial intelligence.
Other companies entering the market of medicines are the British BenevolentAI and Calico, subsidiary of Alphabet. Artificial intelligence, as well as deep learning and machine learning, have shown that there are new ways to develop substances, without having to test them all in a lab. Harvard professor Alán Aspuru-Guzik, for example, has taught a software to combine the properties of different substances to create new drugs. The software uses machine learning algorithms in this process without the intervention of human beings. The exploration is then more intuitive, using the chemical knowledge it has learned, as humans do,” Aspuru-Guzik says. “Human beings could be better chemists having this kind of software as an assistant”.
Cloud computing is another technology that is changing the scenario of medicines development. Clouds are globally accessible at low cost, which enables data to be shared across several regions of the world, allowing a better development of the medications, explains Kevin Julian, Director of Accenture Life Science, a technology management consulting firm. “Animal tests are the kind of information easily shared through the clouds”, explains Arie Halpern. “As these are complicated tests, not all the labs are able to carry them through. In this case, sharing information can be the best option. ” For the biomedical Jackie Hunter, it is only with the use of these technologies that the pharmaceutical industry will be able to keep ahead of the 21st-century requirements.